Last reviewed 2026-04-20 · How we verify

PICODRALAZINE

Phase 2 active Small molecule Quality 19/100

PICODRALAZINE is a picodralazine drug. It is currently in Phase 2 development.

Picodralazine is thought to work by modulating a specific target, although this target has not been identified.

Picodralazine is a small molecule drug in the picodralazine class, but its target and mechanism of action are unknown. Its commercial status and approved indications are also unclear. As a result, there is limited information available on its safety profile, pharmacokinetics, and generic availability. Further research is needed to fully understand this medication. Its development history is also unclear.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PICODRALAZINE
Drug class	picodralazine
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and these locks need a specific key to open. Picodralazine is like a key that fits into one of these locks, but we don't know which lock it is yet. By fitting into the lock, it may help to regulate the activity of the cells.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PICODRALAZINE CI brief — competitive landscape report
PICODRALAZINE updates RSS · CI watch RSS

Frequently asked questions about PICODRALAZINE

What is PICODRALAZINE?

PICODRALAZINE is a picodralazine drug.

How does PICODRALAZINE work?

Picodralazine is thought to work by modulating a specific target, although this target has not been identified.

What drug class is PICODRALAZINE in?

PICODRALAZINE belongs to the picodralazine class. See all picodralazine drugs at /class/picodralazine.

What development phase is PICODRALAZINE in?

PICODRALAZINE is in Phase 2.

Drug class: All picodralazine drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing